Top Data Analytics Companies in NYC, NY (326)

Strong Revenue Growth: Feedback suggests revenue increased for several consecutive quarters, including a 13% year-over-year rise in FY2026 Q4 and an 11% full-year increase to approximately $610 million. Growth is attributed to premium agent-lead products and expansion in seller services, new homes, and rentals.

Strong Market Position & Advantage: Feedback suggests visit share reached about 33% of U.S. real estate portal visits with nearly 300 million monthly visits, indicating competitive traction. Engagement is described as strong, with 5.5 visits per unique user surpassing key competitors on this measure.

Product Line Growth: Feedback suggests expansion of AI-powered search, homeownership tools, and premium offerings like RealPRO Select. These developments are presented as drivers of monetization and deeper platform engagement.

Strong Revenue Growth: Financial disclosures indicate total revenue increased from 2024 to 2025 alongside higher total reported sales, while operating earnings rose sharply. Together these patterns suggest momentum in top line and core operating performance.

Investor Backing & Capital Strength: Total adjusted capital increased from $33.2B to $34.4B, and an estimated $2.9B dividend was approved for eligible policyowners, supported by very strong insurer financial-strength ratings. These signals point to a robust balance sheet that underpins stability and growth capacity.

Diversified Revenue Streams: Expansion was described as broad-based across insurance, annuities, institutional solutions, and wealth management, with client assets in wealth management reaching a record $312B and total AUM at $584B. This mix reduces reliance on any single line of business and supports continued scale.

Strong Revenue Growth: Consolidated revenue is reported higher in 2025 than in 2024, with group figures around PLN 2.9 billion. Parent‑company results also indicate year‑over‑year revenue growth, reinforcing ongoing top‑line momentum.

Profitability: Group profit is reported for 2025 and parent‑company net income rose, suggesting healthy earnings alongside expansion. This points to growth accompanied by positive bottom‑line results.

Product Line Growth: The offering has expanded with ongoing AI‑based product development, a 2026 launch of the self‑service rtb.com platform, and moves into adjacent services via WhitePress. These steps broaden the addressable market and diversify growth avenues.

Investor Backing & Capital Strength: The company secured a $135 million Series D in 2022, bringing total funding to $236 million and a reported billion-plus valuation. This capital base supports continued investment in product and market initiatives.

Strong Market Position & Advantage: The company reports more than 400 enterprise customers, including PepsiCo, Cisco, Nasdaq, Roche, and The New York Times. This breadth points to meaningful enterprise adoption and commercial scale.

Product Line Growth: The platform has expanded from data observability into AI reliability and agent observability, monitoring AI agents in production alongside underlying data pipelines. Company-reported usage metrics—such as 10 million tables monitored and 1,000 incidents resolved daily—indicate a growing product footprint.

Strong Revenue Growth: Revenue is considered to be on an upward trajectory, with sales increasing in 2025 and continuing to rise into the second quarter of 2026. Company updates also indicate an improved full-year outlook, pointing to sustained top-line momentum.

Market Expansion: Geographic performance is described as broad-based, with emerging markets such as Latin America and AMEA cited as key contributors alongside gains in North America. Independent reporting notes that growth is supported across multiple regions rather than a single market alone.

Strong Market Position & Advantage: Category leadership in biscuits and a top-tier position in chocolate, supported by globally recognized brands, are portrayed as competitive advantages. This scale and brand portfolio underpin international distribution across more than 150 countries, aiding growth.

Strong Revenue Growth: Revenue is rising sharply, reaching approximately $4.26–$4.3 billion in FY2026 with about 32% year-over-year growth, alongside multiple quarters of 30%+ revenue increases. GMV also expanded to roughly $50.2 billion, indicating broad-based top-line momentum.

Profitability: Profitability is improving, as operating results shifted from a loss of about $616 million in FY2024 and $87 million in FY2025 to approximately $417 million in operating income in FY2026. Recent quarters also reported positive GAAP operating income and stronger margins.

Product Line Growth: Newer products are scaling quickly, with Affirm Card GMV up roughly 146%–159% year over year and active cardholders more than doubling across recent quarters. Increasing transactions per active consumer and broader merchant adoption reinforce expansion across both core BNPL and card-driven use cases.

Strong Revenue Growth: Revenue has risen consistently, with annual growth in the high single digits and the latest quarter showing double-digit year-over-year increases, and management raising full-year growth guidance. Organic constant-currency expansion in the latest quarter indicates underlying momentum beyond acquisitions and FX.

Profitability: Profitability is improving alongside sales, as net income and adjusted diluted EPS increased year over year in the latest quarter. Full-year results also showed higher net income and adjusted EBITDA.

Market Expansion: Growth appears across U.S. Markets and internationally, with U.S. Financial Services leading and international results positive on an organic constant-currency basis. The company is extending its reach through moves such as acquiring a majority stake in Trans Union de México.

Strong Revenue Growth: Available evidence indicates revenue has risen rapidly, including reported year-over-year growth above 130% and approximately $200 million in annual recurring revenue as of May 2026. The company also describes revenue more than doubling for five consecutive years, signaling accelerating top-line momentum.

Investor Backing & Capital Strength: Successive late-stage rounds in 2026 raised roughly $218 million and lifted the reported valuation from about $1.35 billion to $2.74 billion within months. This pattern points to substantial capital access and confidence from prominent investors.

Strategic Partnerships: Partnerships with organizations such as Mercy, Atlantic Health, Teladoc Health, Marathon Health, and Priority Health are described as expanding distribution and embedding the product within provider and health-plan channels. These relationships broaden commercial reach beyond direct employer sales.

Profitability: Profitability is considered to be improving, with Q2 2026 ex-TAC gross profit up 11.8% year over year, adjusted EBITDA up 22.8%, and net income turning positive. Management also raised full-year guidance for ex-TAC gross profit and adjusted EBITDA despite slower headline revenue.

Innovation-Driven Growth: AI-driven initiatives and newer products such as the Realize platform and DeeperDive are described as key growth engines, contributing to faster ex-TAC gross-profit expansion than total revenue. Taboola News’ broad reach across 80+ countries and 2,000+ publishers further supports product-led expansion.

Strategic Partnerships: Expanded publisher and device relationships, including Fox News and OEM partners like Samsung, Xiaomi, and Motorola, are seen as enlarging distribution and advertiser access. Long-standing large-scale partnerships (e.g., Yahoo-related supply) have historically supported network growth and monetization.

Strong Revenue Growth: Revenue has accelerated, with fiscal Q2 2027 rising 30% year over year to $771.8M after fiscal 2026 grew 23% to $2.46B. Management also raised fiscal 2027 revenue guidance to about $2.99–$3.03B.

Customer Loyalty & Retention: Existing customers are expanding spend, as net revenue retention reached 122% and customers generating at least $100,000 in ARR grew to nearly 3,000. Total customers also increased to roughly 70,600, indicating broadening adoption alongside expansion within accounts.

Healthy Cash Flow: Free cash flow nearly doubled to $137.6M in Q2 FY2027, alongside an improved non-GAAP operating margin of 24% and a swing to positive GAAP net income. Reported cash and short-term investments were approximately $2.4B at quarter-end.

Strong Revenue Growth: Revenue is rising steadily, including 11% year-over-year growth to $192.8 million in Q2 2026 and 7% growth for full-year 2025. The step-up from 6% growth in Q1 2026 to 11% in Q2 indicates accelerating momentum.

Profitability: Adjusted EBITDA increased 30% year over year in Q2 2026 as margin expanded from 34% to 37%, signaling operating leverage. Net income also improved to $19.4 million from $11.1 million year over year in that quarter.

Healthy Cash Flow: Guidance points to free-cash-flow growth in the high-40% range for 2026 alongside adjusted EBITDA growth of more than 20%. Operating cash flow reached $57.4 million in Q2 2026.

Strong Market Position & Advantage: Celonis is repeatedly characterized as the dominant pioneer and market leader in process mining and process intelligence, with sustained recognition from Gartner, Forrester, and Everest and visibility in rankings like the Fortune Future 50 and Forbes Cloud 100. This position is reinforced by a substantial enterprise footprint, including thousands of deployments across more than 20 global locations.

Innovation-Driven Growth: The company is extending beyond traditional dashboards into operational AI, launching its Context Model, adding AI copilots, and agreeing to acquire Ikigai Labs to bolster decision intelligence. These moves signal an evolution toward automated execution and higher platform stickiness among large enterprises.

Strategic Partnerships: Integrations and collaborations with Microsoft, Oracle, AWS, and Databricks embed Celonis within major enterprise data and AI ecosystems. This ecosystem presence expands distribution paths and strengthens its role as an operational context layer for enterprise AI.

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Strong Revenue Growth: Revenue is accelerating, with Q2 2026 rising 22% year over year to $98.7 million and first-half 2026 up about 14%, while management raised full-year revenue guidance to $400–$410 million. This momentum follows relatively modest 2025 growth, indicating a notable reacceleration in 2026.

Healthy Cash Flow: Cash generation improved, with Q2 2026 free cash flow of $12.9 million versus $5.3 million a year earlier and stronger operating leverage reflected in higher adjusted EBITDA. This suggests the business is converting growth into better cash performance even as GAAP profitability remains mixed.

Market Expansion: Business activity is broadening, with Q2 2026 GMV up 13% year over year to $41.3 billion, new merchant wins across all four regions, and expansion into additional payment types like ACH. Rising GMV alongside revenue indicates growth supported by increased platform usage, not just pricing.

Investor Backing & Capital Strength: Recent financing momentum is evident, with a $70M Series C in May 2025 led by Avra and participation from firms such as Andreessen Horowitz, Sequoia, Redpoint, and Snowflake Ventures. This capital is positioned to support further product and go-to-market expansion while signaling confidence in the company’s trajectory.

Market Expansion: Customer adoption appears to be broadening from more than 1,500 teams in May 2025 to more than 2,000 customers globally, including enterprises like Reddit, Figma, HubSpot, Rivian, and Anthropic. Evidence of scaling usage, such as hundreds of millions of usage-based billing events and increased adoption of advanced compute add-ons, reinforces this expansion.

Innovation-Driven Growth: Product momentum centers on AI-powered analytics and agentic workflows, including features like the Notebook Agent and moves into embedded analytics. The acquisition of Hashboard and introduction of usage-based monetization for advanced compute suggest continued innovation aligned with market shifts.

Strong Revenue Growth: Company-reported metrics indicate revenue increased tenfold over four years and bookings rose 10× over three years. Nearly fivefold headcount growth over a similar period reinforces that the business scaled operating capacity alongside top-line gains.

Investor Backing & Capital Strength: A $100 million investment from Blackstone Growth in January 2026, with reporting of an approximately $700 million valuation, signals substantial capital support. This financing is described as fuel for technology development and broader customer expansion.

Diversified Customer Base: The platform is described as serving more than 100 Fortune 500 companies as well as major agencies, trade associations, nonprofits, and advocacy groups. This spread indicates exposure across multiple enterprise and institutional segments rather than dependence on a narrow set of buyers.

Strong Revenue Growth: Reported annual recurring subscription and service revenue grew by more than 220% in 2025, resulting in ARR more than tripling. The increase is attributed to new and expanding relationships with private‑equity sponsors and their portfolio companies.

Market Expansion: Sponsor partnerships are described as having doubled, broadening commercial reach across private‑equity networks. The company also scaled geographically, adding offices in locations such as Chicago, New York, Toronto, Dallas, and Bengaluru.

Product Line Growth: New offerings include the Astradis platform, an AI‑powered pricing suite, expanded healthcare functionality, and the launch of Astra Labs. These additions broaden the addressable market and signal continued investment in AI‑driven solutions.

Strong Revenue Growth: Revenue increased 38% year over year to $427.3M in Q2 FY2027, with subscription revenue up 37% and subscription ARR up 33% to $1.66B. Enterprise adoption is also rising, with customers generating at least $100K in subscription ARR growing from 2,505 to 3,084 year over year.

Healthy Cash Flow: Free cash flow was positive at $65.7M in Q2 FY2027, up from $57.5M a year earlier. Operating leverage is improving as subscription ARR contribution margin increased to 14.0% from 9.4%.

Investor Backing & Capital Strength: Liquidity is substantial, with $1.75B in cash, cash equivalents and short‑term investments as of July 31, 2026. This balance sheet capacity provides flexibility to fund continued growth and execution.

Strong Revenue Growth: Recent financial results highlight sustained top-line expansion with rising quarterly revenue and management increasing full‑year guidance, indicating momentum across 2025 and into 2026.

Diversified Revenue Streams: Growth is coming from both diagnostics and data licensing/AI applications, with testing volumes and data contracts expanding rather than reliance on a single line of business.

Customer Loyalty & Retention: Reported net revenue retention above 100% and sizable remaining contract value suggest existing pharmaceutical customers are deepening engagements.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.